Paliperidone Krka (Paliperidone)

Paliperidone works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors. This antagonism reduces excessive dopamine activity linked to psychosis while balancing serotonin pathways, which together help alleviate hallucinations, delusions, and mood disturbances associated with schizophrenia and related disorders.

The appropriate dose of Paliperidone Krka is determined by the prescribing clinician based on the patient’s condition, response to therapy, and tolerability. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Paliperidone should only be used during pregnancy or lactation if the potential benefits outweigh the risks. Limited data are available, so clinicians assess each case carefully, considering alternative treatments and monitoring both mother and infant closely if the drug is continued.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Paliperidone is the primary active metabolite of risperidone and shares a similar receptor profile, but it offers a longer half‑life allowing once‑daily dosing. Compared with some older antipsychotics, it tends to have a lower risk of certain extrapyramidal symptoms, though metabolic side effects remain a consideration.

Paliperidone Krka should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in areas with high humidity or extreme heat.

Paliperidone Krka is supplied as an oral formulation that is taken by mouth, usually once daily. The tablet should be swallowed whole with water and can be taken with or without food, following the prescriber’s guidance.

Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, seizures, significant orthostatic hypotension, and elevated prolactin levels that may cause hormonal disturbances. Patients should be monitored regularly for these conditions, and any concerning symptoms should be reported promptly.

Paliperidone is contraindicated in patients with known hypersensitivity to paliperidone or any of its excipients, and it should be used with caution in individuals with severe cardiovascular disease, uncontrolled diabetes, or a history of neuroleptic malignant syndrome. A healthcare professional must evaluate suitability before initiating therapy.